2022 World Conference on Lung Cancer (ePosters)-EP16.03-031. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants

EP16.03-031. Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants

Back to course

Pdf Summary

A study was conducted to analyze the transcriptomic heterogeneity in non-small cell lung cancer (NSCLC) patients with different variants of EGFR Exon 19 Del/Delins. The study found that there is significant heterogeneity in the gene expression profiles of NSCLC patients with these EGFR variants. <br /><br />The study analyzed NGS data from 1242 patients with EGFR 19del/19delins variants and further examined the gene expression data of 81 patients. It identified a total of 48 different EGFR 19Del/Delins variants. The patients were divided into classic 19del subtype group and atypical mutations group. The atypical mutations group included 19del group and 19delins group.<br /><br />The study found that the transcriptomic heterogeneity varied among different EGFR variants. Tumors with 19dels starting from E746 displayed activation of FGFR1/2 cascades, while tumors with variants starting from L747 showed upregulation of cell cycle-related pathways. Tumors with uncommon 19delins displayed enrichment of immune-related pathways.<br /><br />The researchers also found that the response to EGFR-TKIs (tyrosine kinase inhibitors) varied depending on the EGFR variant. It was reported that NSCLC patients with certain EGFR 19Del/Delins variants responded differently to EGFR-TKIs. This highlights the importance of understanding the biological heterogeneity of NSCLC with different EGFR Exon 19Del/Delins variants.<br /><br />The study concluded that NSCLC with EGFR 19 Del/Delins should not be considered a homogeneous disease and that there is significant transcriptomic heterogeneity among different EGFR variants. The findings suggest that NSCLC patients with uncommon EGFR 19Del/Delins variants may have a more active adaptive immunity in the tumor microenvironment, indicating the potential vulnerability of immunotherapy. However, further research is needed to understand the implications of these findings and to explore the potential use of immunotherapy in NSCLC patients with different EGFR variants.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

transcriptomic heterogeneity

non-small cell lung cancer

NSCLC

EGFR Exon 19 Del/Delins

gene expression profiles

NGS data

classic 19del subtype group

atypical mutations group

EGFR-TKIs

tumor microenvironment